The Hodgkin's Disease.6 study is critically examined, and the question of whether or not radiation should be used at all in the treatment of patients with limited-stage Hodgkin's lymphoma is argued to be more relevant than what type of radiation to use, given the remarkably good outcome with chemotherapy alone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425518 | PMC |
| http://dx.doi.org/10.1634/theoncologist.2012-0228 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Maximum Tumor Diameter is Associated with Relapse Risk in Limited-Stage Hodgkin Lymphoma: An International Study.
Blood Adv
January 2025
Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, and Department of Medical Oncology, The Christie Hospital, Manchester, United Kingdom.
Tumour bulk is an established prognostic factor in Hodgkin lymphoma (HL) but most patients with limited-stage (LS) HL do not have 'bulk' by standard binary definitions. In the RAPID trial, maximum tumor diameter (MTD) was associated with risk of relapse for LS-HL patients achieving PET-negativity after ABVD chemotherapy. We aimed to externally validate these findings in the H10 trial.
View Article and Find Full Text PDFSingle gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.
Br J Haematol
November 2024
Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Radiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69-gene panel in 117 limited-stage FL patients treated with radiotherapy and identified recurrently mutated genes.
View Article and Find Full Text PDFTreatment approaches for older Hodgkin lymphoma patients.
Curr Opin Oncol
September 2024
University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD).
Purpose Of Review: Hodgkin lymphoma (HL) occurs at two age peaks around 25 and 60 years of age. Due to varying fitness and co-morbidities older patients are a heterogeneous group that has relatively poor treatment outcomes. The evolving therapeutic landscape for older HL is summarized herein.
View Article and Find Full Text PDFCD14CD10CD45HLA-DRSSC neutrophils may be granulocytic myeloid-derived suppressor cell-like cells and relate to disease progression in non-Hodgkin's lymphoma patients.
Immunol Cell Biol
April 2024
School of Nursing, Anhui Medical University, Hefei, China.
We explored the frequency of CD14CD10CD45HLA-DRSSC neutrophils (CD10 neutrophils) in patients with non-Hodgkin's lymphoma (NHL), and their immunologic characteristics and clinical significance. Patients with NHL who were newly diagnosed (NDP; n = 33), in remission (RMP; n = 28) and relapsed (RLP; n = 29) were included, and 47 volunteers were recruited as healthy controls (HCs). The frequency of CD10 neutrophils in the peripheral blood from HC and patients with NHL was detected.
View Article and Find Full Text PDFBackground: ABVD (doxorubicin, bleomycin, vinblastine, and dexamethasone) is a proven, curative regimen for Hodgkin lymphoma (HL). Prospective data describing HL treatment in sub-Saharan Africa are limited. We aimed to fill this knowledge gap, using data from Malawi.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!